[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mitral-valve-repair\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mitral-valve-repair":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,55],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":34,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100626363","phase-3-apixaban-vs-warfarin-in-af-pts-first-three-months-after-repair-or-bio-avr-mvr-100626363",false,"NCT07434661","Apixaban VS Warfarin in AF Pts First Three Months After Repair or BIO AVR MVR","Safety and Efficacy of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation in the First Three Months After Mitral or Aortic Biological Valve Replacement or Repair","SAFE-HEART","Inclusion Criteria:\n\n* Age ≥18 years at the time of enrolment\n* Open heart aortic or mitral valve repair or biological valve replacement in the last 10 days\n* Atrial fibrillation requiring anticoagulation (including pre-existing or post-operative atrial fibrillation),\n* Informed consent from either the patient or a substitute decision-maker.\n\nExclusion Criteria:\n\n* Mechanical valve replacement\n* Antiphospholipid syndrome (triple positive)\n* Severe renal failure (Cockcroft-Gault equation; creatinine clearance \\\u003C15 ml\u002Fmin)\n* Known significant liver disease (Child-Pugh classification B and C)\n* Left ventricular thrombus\n* Ongoing bleeding, hemorrhagic disorders, or bleeding diathesis\n* Known contraindication for any DOAC or VKA\n* Women who are pregnant, breastfeeding, or of childbearing potential\n* Follow-up not possible","ALL","18 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","SAFE-HEART is a single-centre, randomized controlled trial comparing the safety and efficiency of Apixaban versus Warfarin in the early period (3 months) after repair or bioprosthetics of the mitral and aortic valve cardiac surgery in patients with atrial fibrillation requiring oral anticoagulation.",[27,28,29,30,31,32,33],"Valve Disease, Heart","Atrial Fibrillation (AF)","Valve Replacement Surgery","Aortic Valve Surgery","Mitral Valve Annuloplasty","Mitral Valve Repair","Mitral Valve Surgery",[35,36,37,38,39,40,41],"anticoagulation","bioprosthetics","atrial fibrillation","mitral valve repair","aortic valve repair","Apixaban","Warfarin","NOT_YET_RECRUITING","2026-02-20",{"date":45,"type":46},"2026-02-25","ACTUAL",{"date":48,"type":21},"2026-02",{"date":50,"type":21},"2029-01",{"name":52,"class":53},"Meshalkin Research Institute of Pathology of Circulation","NETWORK",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":62,"targetDuration":64,"studyType":65,"phases":4,"briefSummary":66,"conditions":67,"keywords":76,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":54},"100617119","cardiological-interventions-and-acute-stroke-treatment-study-100617119","NCT07314476","CardioLogical Interventions and Acute strOke Treatment sTudy","CLOT","Inclusion Criteria:\n\n* acute ischemic stroke in adult patient (18 years of age or older) as diagnosed according to the World Health Organization (WHO) criteria;\n* stroke with evidence of CT\u002FMRI DWI\u002FFLAIR acute lesion in the first neuroimaging or in the follow-up at 24-48 h;\n* interventional cardiological procedures performed within 28 days since the stroke onset (Percutaneuous Coronary Intervention - PCI, Transcatheter Aortic Valve Replacement - TAVR, Baloon Aortic Valvuloplasy - BAV, Percutaneous Mitral Valve Repair or Replacement, Patent Formaen Ovale - PFO - or Atrial Septal Defects - ASD - Closure, Left Atrial Appendage Closure, Transcatheter Pulmonary Valve Replacement, Percutaneous Closure of Paravalvular Leaks);\n* written informed consent provided by the patient himself or by proxy (for unconscious patients, cognitively impaired, or aphasic).\n\nExclusion Criteria:\n\n* Stroke-like symptoms due primarily to another non-ischemic\u002Fhemorrhagic acute neurological condition or stroke mimics (e.g. severe hypo- or hyperglycemia, migraine with aura, functional disorders, etc);\n* Spontaneous and post traumatic hemorrhagic stroke or spontaneous\u002Fpost-traumatic subarachnoid hemorrhage or subdural hematoma;\n* AciuImpossibility to achieve written informed consent",{"count":63,"type":21},400,"180 Days","OBSERVATIONAL","The study aims to investigate characteristics and prognosis of ischemic stroke cases following cardiological interventions, focusing on the effectiveness and safety of acute ischemic stroke treatments.",[68,69,70,71,72,32,73,74,75],"Acute Ischemic Stroke AIS","Stroke Treatment","PCI Patients","Aortic Valve Replacement","Transcatheter Aortic Valve Replacement (TAVR)","Mitral Valve Replacement","Left Atrial Appendage Closure","Transcatheter Pulmonary Valve Replacement (TPVR)",[77,78,79],"acute ischemic stroke","acute ischemic stroke treatments","cardiological intervention","2026-01-04",{"date":82,"type":46},"2026-01-07",{"date":84,"type":21},"2026-01",{"date":86,"type":21},"2028-12",{"name":88,"class":89},"University of L'Aquila","OTHER"]